TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9366768
Drug: Sodium heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin, EDTA, lithium heparin
Study: 3935455
Drug: Metolazone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (2.5 mg orally after 6 hours of furosemide infusion)
Study: 3935455
Drug: Furosemide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (4 mg h‐1 intravenous infusion for 12 hours)
Study: 30082326
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW (2-mg subcutaneous injection) plus dapagliflozin (10-mg oral tablet)
Study: 30082326
Drug: Exenatide QW
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide QW (2-mg subcutaneous injection)
Study: 30082326
Drug: Dapagliflozin (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10-mg oral tablet)
Study: 24780614
Drug: Eplerenone (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25-50 mg once daily)
Study: 9755021
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (A and B) vs Control group (C)
Study: 3041785
Drug: Terodiline hydrochloride
Normalized name: Terodiline hydrochloride
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terodiline hydrochloride (24 mg/day)
Study: 3041785
Drug: Flavoxate hydrochloride
Normalized name: Flavoxate Hydrochloride
DrugBank: Flavoxate (DB01148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flavoxate hydrochloride (600 mg/day)
Study: 18716827
Drug: Topical piroxicam
Normalized name: piroxicam Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical piroxicam
Study: 28292867
Drug: Best Medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Medical Therapy (Control)
Study: 21944653
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (12 sessions of 30 minutes each)
Study: 3557003
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg oral doses for 4 days)
Study: 3557003
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg single oral dose)
Study: 31329610
Drug: MERM device
Approvals — FDA: no, EMA: no, PMDA: no
Description: MERM device with daily alert and scheduled dosing history review
Study: 26082623
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with long-acting anticholinergic drugs
Study: 23515006
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.16 g DHA/d)
Study: 18188660
Drug: physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: physical therapy (hot pack, ultrasound, TENS) + home exercise
Study: 12923829
Drug: Diazepam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (12 or 18 mg/day)
Study: 12923829
Drug: Diazepam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (6 mg/day)
Study: 11100393
Drug: Low-dose adrenomedullin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adrenomedullin (ADM, 1, 2 and 3 pmol kg‐1 min‐1 for 30 min each)
Study: 3901956
Drug: Nondominant unilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondominant unilateral electroconvulsive therapy (ECT)
Study: 29926979
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri 6475 (1010 colony-forming units daily)
Study: 27689192
Drug: Split-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose regimen of sodium picosulfate/magnesium citrate (SPMC)
Study: 25362223
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin), 0.5 mg/kg at the beginning of each hemodialysis session
Study: 25362223
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UF heparin), 5000 units
Study: 22647278
Drug: Jumping exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jumping exercise intervention (supervised jumping protocol during the first 10 min of physical education class, twice a week for 9 months)
Study: 20306185
Drug: Metronidazole 500
Normalized name: metronidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 500 mg three times daily for 7 days
Study: 3047920
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of iron per day, as ferrous gluconate
Study: 29380821
Drug: Gluten (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (10 g/daily)
Study: 8607960
Drug: loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (10 mg by mouth daily)
Study: 8607960
Drug: terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine (60 mg by mouth twice daily)
Study: 24103462
Drug: Buccal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal fat pad (BFP) (Group II, n = 10)
Study: 23477161
Drug: Maixuekang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maixuekang capsule combined with conventional therapy for 3 months
Study: 29648531
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg tablet)
Study: 29648531
Drug: Ritmonorm® (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritmonorm® (300 mg tablet)
Study: 17288686
Drug: Desloratadine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5 mg
Study: 17288686
Drug: Desloratadine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5 mg plus alcohol (0.1% BAC)
Study: 17288686
Drug: Desloratadine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 7.5 mg vs. placebo with alcohol
Study: 12140664
Drug: Flupirtine 50
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine 50 mg
Study: 9987141
Drug: Adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted influenza vaccine (FLUAD, Chiron Vaccines)
Study: 9987141
Drug: Conventional non-adjuvanted
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-adjuvanted influenza vaccine
Study: 7762525
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg beta-carotene/d for 6 d as synthetic all-trans-beta-carotene
Study: 7762525
Drug: Natural beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural beta-carotene preparation (50:50 mixture of all-trans- and 6-cis-beta-carotene)
Study: 7762525
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg all-trans-beta-carotene or either 66 or 100 mg of the natural 50:50 isomeric mixture (alternate-day supplementation for 23 d)
Study: 17335365
Drug: Subgingival chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival chlorhexidine varnish administration
Study: 15252293
Drug: Sertraline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (200 mg/day) for 14 weeks
Study: 10201553
Drug: 7.0 g
Normalized name: OCTINOXATE 7.0 g in 100 g TOPICAL LIPSTICK [TREATMENT LIPSHINE SPF 15]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.0 g ispaghula/day
Study: 10201553
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g ispaghula/day
Study: 23331802
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered to 32 patients for 3 months post-pullthrough
Study: 23331802
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered for 3 months post-pullthrough
Study: 19748859
Drug: Echinacea/sage spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea/sage spray
Study: 19748859
Drug: Chlorhexidine/lidocaine spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine/lidocaine spray
Study: 18193695
Drug: Secnidazole tablet
DrugBank: Secnidazole (DB12834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secnidazole tablet (reference)
Study: 18193695
Drug: Secnidazole capsule
DrugBank: Secnidazole (DB12834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secnidazole capsule (test)
Study: 15867048
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (continuing omega-3 and omega-6 fatty acids)
Study: 12186120
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AMP-LRC-1)
Study: 7867677
Drug: Desmin 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 370 (100 mg)
Study: 7867677
Drug: Desmin 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 370 (200 mg)
Study: 7867677
Drug: Desmin 370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 370 (100 mg and 200 mg)
Study: 773589
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methyl‐CCNU and imidazole carboxamide (DTIC)
Study: 15215815
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus Clopidogrel
Study: 30783954
Drug: Control (Healthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Healthy subjects receiving no-stent or antiplatelet therapy)
Study: 21469195
Drug: Ropinirole prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole prolonged release (PR) 2-24 mg/d
Study: 21469195
Drug: Ropinirole immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole immediate release (IR) 0.75-24 mg/d
Study: 2153006
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg orally every 12 hours)
Study: 2153006
Drug: Vancomycin/polymyxin (vancomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin/polymyxin (vancomycin 500 mg orally every 8 hours and polymyxin 100 mg orally every 8 hours)
Study: 6383735
Drug: 0.1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 percent amcinonide cream
Study: 391500
Drug: 0.1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 percent betamethasone valerate cream
Study: 31439681
Drug: High-risk CC
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk CC genotype
Study: 19114895
Drug: Alkaline phosphatase
Normalized name: Alkaline phosphatase
DrugBank: Alkaline Phosphatase (DB05768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline phosphatase (AP) treatment
Study: 15230337
Drug: Rabeprazole formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole formulation 1
Study: 15230337
Drug: Rabeprazole formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole formulation 2
Study: 12227646
Drug: DCLHb (10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb (10% solution, approximately 1000 mg/kg)
Study: 7631339
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (air)
Study: 378317
Drug: Mysteclin syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mysteclin syrup (tetracycline hydrochloride and amphotericin) used as a mouthwash
Study: 21864626
Drug: 1mg intradermally
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg intradermally (id) HIV‐DNA vaccine
Study: 21864626
Drug: 3.8mg intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8mg intramuscularly (im) HIV‐DNA vaccine
Study: 21864626
Drug: HIV‐DNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐DNA vaccine
Study: 17763935
Drug: therapy to
Normalized name: COOL THERAPY Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: therapy to normalize homocysteine plasma level
Study: 17763935
Drug: no therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: no therapy to normalize homocysteine plasma level
Study: 16445556
Drug: Buprenorphine (8-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (8-24 mg/day)
Study: 16445556
Drug: Methadone (40-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (40-100 mg/day)
Study: 12563623
Drug: Sorbifer Durules
Normalized name: iron sorbitex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbifer Durules (1 tablet/d) for 4 weeks
Study: 8901659
Drug: Moderate oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate oral anticoagulation (INR 2.0 to 3.0)
Study: 8901659
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral anticoagulation (INR 3.0 to 4.5)
Study: 6176321
Drug: Involved-field radiotherapy
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved-field radiotherapy plus six courses of MOPP chemotherapy
Study: 6176321
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (MOPP-bleomycin)
Study: 26314308
Drug: Low-osmolarity oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolarity oral rehydration solution (ORS) (osmolarity: 245, sodium: 75) with added potassium (20 mmol/l)
Study: 23364255
Drug: rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (20 mg 2-4 hours before PCI)
Study: 21371128
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere 0.04% or 0.1%
Study: 20469685
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) at a dose of 10 mg/kg body weight once at night for 3 months
Study: 15164114
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron supplementation (Fe group; n=978)
Study: 15164114
Drug: Combined supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplementation of 10,000 IU vitamin A and 60 mg iron (VAFe group; n=1042)
Study: 11529465
Drug: Up-front SCT
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up-front SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Study: 11529465
Drug: Salvage SCT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage SCT with Dexa-BEAM chemotherapy followed by myeloablative regimens
Study: 7515507
Drug: Prednisone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (80 mg/day for 5 days)
Study: 7515507
Drug: Acute dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acute dexamethasone administration
Study: 7515507
Drug: Chronic corticosterone
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic corticosterone administration
Study: 3652932
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring program for theophylline
Study: 3652932
Drug: Reinstatement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstatement of the therapeutic drug monitoring program
Study: 31904295
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) + Treatment as Usual (TAU)
Study: 31046423
Drug: Dabigatran (high-dose)
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (high-dose)
Study: 31046423
Drug: Dabigatran (low-dose)
Normalized name: ethinyl estradiol
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran (low-dose)
Study: 26152434
Drug: Gabby (conversational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabby (conversational agent system)
Study: 20534818
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg) administered with a standard high-fat meal
Study: 20534818
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg) administered in a fasted state
Study: 19671472
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder (20 g/day) with 250 mL of skimmed milk
Study: 19671472
Drug: Skimmed milk
Normalized name: Calcium fortified skimmed milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skimmed milk (500 mL/day)
Study: 17273659
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg/day (N = 20)
Study: 17273659
Drug: Metformin, 1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 1.7 g/day (N = 21)
Study: 8555780
Drug: Automated blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated blood grouping by gel technology (ID-Sampler II)
Study: 8555780
Drug: Routine microtitre
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine microtitre plate and gel techniques
Study: 2925055
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Is‐5‐Mn
Study: 2925055
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Is‐5‐Mn
Study: 27643690
Drug: Licorice flavonoid
Normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice flavonoid oil (LFO) 300 mg/day for 16 weeks
Study: 27643690
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one capsule/day for 16 weeks)
Study: 22893557
Drug: 3 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL/kg calfactant by LMA (experimental)
Study: 20687194
Drug: Narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative therapy (NT) plus escitalopram
Study: 15516378
Drug: Focused ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused ultrasound therapy
Study: 8005254
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg codeine
Study: 18626140
Drug: Chlorpheniramine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (12 mg)
Study: 18626140
Drug: Chlorpheniramine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine plus ephedrine (Chlorphedra: 12 mg C + 50 mg ephedrine)
Study: 9261702
Drug: Targeted antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted antibiotics (for TBSA ≥ 35%)
Study: 3536400
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sucralfate suspension four times daily
Study: 1484022
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine tablet twice daily
Study: 18338263
Drug: Neostigmine 2
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2 mg and glycopyrrolate 0.4 mg intramuscularly
Study: 1403999
Drug: Couple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couple therapy (five sessions)
Study: 1403999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no couple therapy)
Study: 2988737
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy twice a week (40.00 Gy/5 weeks) with misonidazole 1.2 g/m2 given orally 3 1/2 to 4 hours before treatment
Study: 2988737
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy twice a week (40.00 Gy/5 weeks) with placebo
Study: 2988737
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy five times a week (50.00 Gy/5 weeks) with misonidazole 0.48 g/m2 given orally 3 1/2 to 4 hours before treatment
Study: 2988737
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy five times a week (50.00 Gy/5 weeks) with placebo
Study: 2988737
Drug: CCNU chemotherapy
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCNU chemotherapy (120 mg/m2 every 6 weeks)
Study: 27600013
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia and patient-controlled intravenous analgesia (PCIA)
Study: 19255992
Drug: Sublingual midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sublingual midazolam (0.3 mg/kg)
Study: 9877257
Drug: Parents as
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents as the agents of change (experimental intervention)
Study: 9877257
Drug: Children as
Normalized name: AZELASTINE HYDROCHLORIDE 205.5 ug NASAL SPRAY, METERED [Children Astepro Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children as the agents of change (conventional intervention)
Study: 8078438
Drug: Cyclic parenteral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic parenteral nutrition
Study: 8078438
Drug: Continuous nutrient
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nutrient infusion
Study: 30629770
Drug: G + T
Normalized name: Gemcitabine + Trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: G + T
Study: 24392462
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (72 patients)
Study: 19887581
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum total cholesterol concentration (high versus low quintile, >276.7 versus <203.9 mg/dL)
Study: 19887581
Drug: Greater HDL
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater HDL cholesterol (high versus low quintile, >55.3 versus <36.2 mg/dL)